# A Phase III Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Investigational Product MP-101 in Subjects With Short Bowel Syndrome Who Have Had an Inadequate Response to Anti-Diarrheals

> **NCT02242656** · PHASE3 · WITHDRAWN · sponsor: **Marathon Pharmaceuticals, LLC**

## Conditions studied

- Short Bowel Syndrome
- Short Gut Syndrome
- SBS
- Short Bowel
- Short Gut

## Interventions

- **DRUG:** Opium Tincture USP Deodorized
- **DRUG:** Opium Tincture USP Deodorized

## Key facts

- **NCT ID:** NCT02242656
- **Lead sponsor:** Marathon Pharmaceuticals, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-12
- **Primary completion:** 2017-12
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Transfer of IND to new marketing authorization holder
- **Last updated:** 2015-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02242656

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02242656, "A Phase III Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Investigational Product MP-101 in Subjects With Short Bowel Syndrome Who Have Had an Inadequate Response to Anti-Diarrheals". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02242656. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*